

[Open Peer Review on Qeios](#)

HLA-A*2402-Restricted URLC10-TTK-KOC1 Multipeptide Vaccine

National Cancer Institute

Source

National Cancer Institute. *HLA-A*2402-Restricted URLC10-TTK-KOC1 Multipeptide Vaccine*. NCI Thesaurus. Code C77897.

A cancer vaccine containing three HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from URLC10 (up-regulated lung cancer 10); TTK (TTK protein kinase); and KOC1 (IGF II mRNA Binding Protein 3). Upon administration, URLC10-TTK-KOC1 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, TTK and KOC1 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8⁺ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.